Total Payments
$37,078
2024 Payments
$4,586
Companies
17
Transactions
81
Medicare Patients
869
Medicare Billing
$168,711
Payment Breakdown by Category
Consulting$16,103 (43.4%)
Research$9,563 (25.8%)
Other$6,915 (18.6%)
Food & Beverage$2,420 (6.5%)
Travel$2,051 (5.5%)
Education$26.06 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $16,103 | 7 | 43.4% |
| Unspecified | $9,563 | 26 | 25.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,915 | 3 | 18.6% |
| Food and Beverage | $2,420 | 30 | 6.5% |
| Travel and Lodging | $2,051 | 13 | 5.5% |
| Education | $26.06 | 2 | 0.1% |
Payments by Type
General
$27,515
55 transactions
Research
$9,563
26 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Verastem, Inc. | $12,617 | 9 | $0 (2020) |
| Regeneron Pharmaceuticals, Inc. | $9,674 | 27 | $0 (2024) |
| Kyowa Kirin, Inc. | $5,114 | 11 | $0 (2024) |
| Seagen Inc. | $3,807 | 7 | $0 (2023) |
| Seattle Genetics, Inc. | $2,389 | 9 | $0 (2019) |
| Daiichi Sankyo Inc. | $1,528 | 1 | $0 (2021) |
| Celgene Corporation | $694.89 | 3 | $0 (2024) |
| Secura Bio, Inc. | $303.61 | 2 | $0 (2024) |
| Eli Lilly and Company | $250.46 | 3 | $0 (2023) |
| Gilead Sciences Inc | $250.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,586 | 16 | Regeneron Pharmaceuticals, Inc. ($3,236) |
| 2023 | $3,418 | 16 | Regeneron Pharmaceuticals, Inc. ($3,194) |
| 2022 | $2,662 | 7 | Regeneron Pharmaceuticals, Inc. ($2,371) |
| 2021 | $1,539 | 2 | Daiichi Sankyo Inc. ($1,528) |
| 2020 | $10,223 | 7 | Verastem, Inc. ($6,525) |
| 2019 | $14,126 | 27 | Verastem, Inc. ($6,092) |
| 2018 | $95.12 | 2 | Seattle Genetics, Inc. ($95.12) |
| 2017 | $429.54 | 4 | Gilead Sciences Inc ($250.00) |
All Payment Transactions
81 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | Kyowa Kirin, Inc. | Poteligeo (Drug) | Food and Beverage | In-kind items and services | $45.35 | General |
| Category: Monoclonal Antibody | ||||||
| 12/07/2024 | Pierre Fabre Pharmaceuticals, Inc. | TABELECLEUCEL (Drug) | Food and Beverage | In-kind items and services | $65.00 | General |
| Category: PEDIATRIC DERMATOLOGY | ||||||
| 10/25/2024 | Secura Bio, Inc. | COPIKTRA (Drug) | Food and Beverage | In-kind items and services | $151.87 | General |
| Category: ORAL ONCOLOGIC | ||||||
| 09/05/2024 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 09/05/2024 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 09/04/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $2,133.32 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 08/01/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $179.58 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 07/15/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $254.29 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 07/15/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $204.29 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 06/20/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $139.17 | General |
| Category: Oncology | ||||||
| 06/15/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $306.36 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 06/06/2024 | Secura Bio, Inc. | COPIKTRA (Drug) | Food and Beverage | In-kind items and services | $151.74 | General |
| Category: ORAL ONCOLOGIC | ||||||
| 06/06/2024 | PFIZER INC. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $62.98 | General |
| Category: Oncology | ||||||
| 02/23/2024 | PFIZER INC. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $53.86 | General |
| Category: Oncology | ||||||
| 02/22/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $158.38 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 01/19/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $79.80 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2023 | Lilly USA, LLC | JAYPIRCA (Drug) | Food and Beverage | In-kind items and services | $23.52 | General |
| Category: Oncology | ||||||
| 12/10/2023 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $578.50 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 12/10/2023 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $369.03 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 12/10/2023 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $225.81 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 12/08/2023 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $104.20 | General |
| 12/08/2023 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $21.28 | General |
| 10/02/2023 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $244.79 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 10/02/2023 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $112.90 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 07/27/2023 | Seagen Inc. | — | Food and Beverage | In-kind items and services | $75.77 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | Regeneron Pharmaceuticals, Inc. | $8,730 | 22 |
| An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory Follicular Lymphoma | Regeneron Pharmaceuticals, Inc. | $833.74 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 253 | 551 | $311,586 | $49,961 |
| 2022 | 5 | 183 | 415 | $212,629 | $37,465 |
| 2021 | 6 | 229 | 445 | $219,383 | $40,511 |
| 2020 | 7 | 204 | 505 | $250,315 | $40,774 |
Total Patients
869
Total Services
1,916
Medicare Billing
$168,711
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 45 | 249 | $151,392 | $22,859 | 15.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 64 | 134 | $79,194 | $14,148 | 17.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 76 | 100 | $41,840 | $7,119 | 17.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 28 | 28 | $26,306 | $3,894 | 14.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 26 | 26 | $7,072 | $1,075 | 15.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 14 | 14 | $5,782 | $866.04 | 15.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 56 | 145 | $77,741 | $16,408 | 21.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 21 | 135 | $74,655 | $10,764 | 14.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 63 | 91 | $34,429 | $6,451 | 18.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 23 | 24 | $20,864 | $3,217 | 15.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 20 | 20 | $4,940 | $625.50 | 12.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 55 | 123 | $64,447 | $14,084 | 21.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 34 | 137 | $73,569 | $11,219 | 15.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 74 | 117 | $43,563 | $8,262 | 19.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 33 | 33 | $26,572 | $4,724 | 17.8% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 22 | 22 | $8,008 | $1,239 | 15.5% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 11 | 13 | $3,224 | $983.84 | 30.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 40 | 214 | $111,494 | $17,493 | 15.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 47 | 158 | $80,342 | $13,646 | 17.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 56 | 68 | $24,392 | $3,719 | 15.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 15 | 15 | $10,924 | $2,014 | 18.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 11 | 11 | $10,912 | $1,614 | 14.8% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 23 | 25 | $8,825 | $1,441 | 16.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 12 | 14 | $3,426 | $848.00 | 24.8% |
About Dr. Deepa Jagadeesh, M.D
Dr. Deepa Jagadeesh, M.D is a Internal Medicine healthcare provider based in Worcester, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/22/2007. The National Provider Identifier (NPI) number assigned to this provider is 1720131766.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Deepa Jagadeesh, M.D has received a total of $37,078 in payments from pharmaceutical and medical device companies, with $4,586 received in 2024. These payments were reported across 81 transactions from 17 companies. The most common payment nature is "Consulting Fee" ($16,103).
As a Medicare-enrolled provider, Jagadeesh has provided services to 869 Medicare beneficiaries, totaling 1,916 services with total Medicare billing of $168,711. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Worcester, MA
- Active Since 01/22/2007
- Last Updated 11/19/2008
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1720131766
Products in Payments
- Copiktra (Drug) $12,617
- ADCETRIS (Biological) $6,061
- POTELIGEO (Drug) $5,069
- COPIKTRA (Drug) $303.61
- Zydelig (Drug) $250.00
- BRUKINSA (Drug) $139.17
- VENCLEXTA (Drug) $79.80
- SGN-CD33A (Biological) $70.09
- TABELECLEUCEL (Drug) $65.00
- Poteligeo (Drug) $45.35
- JAYPIRCA (Drug) $23.52
- Imbruvica (Drug) $14.56
- TAZVERIK (Drug) $11.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Worcester
Jonathan Kay, Md, MD
Internal Medicine — Payments: $341,486
Internal Medicine $341,486
Leslie Harrold, M.d, M.D
Internal Medicine — Payments: $81,558
Internal Medicine $81,558
Bogdan Nedelescu, M.d, M.D
Internal Medicine — Payments: $50,128
Internal Medicine $50,128
Nikhil Shah, M.d, M.D
Internal Medicine — Payments: $39,924
Internal Medicine $39,924
Dr. Julia Andrieni, M.d, M.D
Internal Medicine — Payments: $35,880
Internal Medicine $35,880
Jan Cerny, M.d, M.D
Internal Medicine — Payments: $33,653
Internal Medicine $33,653